Hohimer Wealth Management LLC Has $2.70 Million Position in Danaher Co. (NYSE:DHR)

Hohimer Wealth Management LLC increased its holdings in shares of Danaher Co. (NYSE:DHR) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,654 shares of the conglomerate’s stock after acquiring an additional 183 shares during the period. Hohimer Wealth Management LLC’s holdings in Danaher were worth $2,696,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in DHR. BKM Wealth Management LLC bought a new position in Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. bought a new position in Danaher during the 4th quarter valued at about $29,000. Rakuten Securities Inc. bought a new position in Danaher during the 4th quarter valued at about $36,000. Financial Connections Group Inc. bought a new position in Danaher during the 4th quarter valued at about $41,000. Finally, Frazier Financial Advisors LLC bought a new position in Danaher during the 4th quarter valued at about $44,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders sold 172,540 shares of company stock worth $43,523,481 over the last quarter. 11.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DHR. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Bank of America boosted their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Barclays boosted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Finally, Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Trading Down 2.1 %

NYSE DHR traded down $5.62 during trading on Thursday, reaching $261.57. 1,783,775 shares of the stock traded hands, compared to its average volume of 2,686,670. The firm has a market cap of $193.74 billion, a price-to-earnings ratio of 45.31, a price-to-earnings-growth ratio of 4.08 and a beta of 0.83. The stock’s 50-day moving average price is $249.54 and its 200 day moving average price is $238.04. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $268.98.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.36 earnings per share. Analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.